Article
Oncology
Catherine Sarre-Lazcano, Sinziana Dumitra, Marco Fiore
Summary: Pelvic soft tissue sarcomas (PSTS) are a rare and heterogeneous group of tumors that differ from retroperitoneal sarcomas (RPS). Adequate imaging and preoperative biopsy are crucial for differential diagnosis and treatment planning. Surgical approach and multidisciplinary teamwork are essential due to anatomic constraints and potential complications. Early referral to specialized centers is recommended for optimal resection and improved survival. International consensus on PSTS treatment is needed, similar to recent efforts for RPS.
Article
Health Care Sciences & Services
Ke Pang, Xiaoning Guo, Tang Liu, Lu Wang, Ruiqi Chen, Zhiming Zhang, Lan Li, Yu He, Haixia Zhang, Songqing Fan, Chao Tu, Zhihong Li
Summary: A multidisciplinary team plays a significant role in the diagnosis and treatment of bone and soft tissue sarcomas, improving preoperative diagnostic accuracy and guiding treatment decisions for certain cases.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Paolo Spinnato, Michele Kind, Francois Le Loarer, Giuseppe Bianchi, Marco Colangeli, Andrea Sambri, Federico Ponti, Kirsten van Langevelde, Amandine Crombe
Summary: This article provides an overview of the current standard of care for patients with locally advanced STS, and summarizes the methods and limitations for evaluating response to neoadjuvant treatment, including the methods used in clinical practice and clinical trials, quantitative MRI sequences, and texture analysis.
ACADEMIC RADIOLOGY
(2022)
Review
Oncology
Changkai Zhou, Xue Chen, Ying Huang, Qi Zhang, Shu Zhu, Wei Fu
Summary: This article discusses the progress made in the use of nanotechnology for the diagnosis and treatment of soft tissue sarcomas (STS) and highlights the future prospects of STS multimodality therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Andrea Ferrari, Daniel Orbach, Monika Sparber-Sauer, David O. Walterhouse, Kristian W. Pajtler, William H. Meyer, Sheri L. Spunt, Aaron R. Weiss
Summary: This article discusses the clinical heterogeneity of non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), which can affect children and adolescents, and the controversies and challenges in managing these tumors. The INSTRuCT project provides a unique mechanism for increasing international collaboration.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Dietmar Dammerer, Johannes Neugebauer, Matthias Braito, Moritz Wagner, Markus Neubauer, Lukas Moser, Markus Suess, Michael Liebensteiner, David Putzer
Summary: Soft tissue sarcomas are rare malignant tumors originating in the mesenchyme, with over 80 different types identified. This study investigated the local recurrence rate in 35 individuals with soft tissue sarcomas treated at the University Hospital for Orthopaedics Innsbruck from 2010-2016. The treatment regimen consisting of surgical resection, radiotherapy, and chemotherapy achieved high local control rates for extremities and retroperitoneal sarcomas.
Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Review
Oncology
Andrea York Tiang Teo, Vivian Yujing Lim, Valerie Shiwen Yang
Summary: Soft tissue sarcoma is a rare cancer that accounts for 1% of adult cancers and 20% of pediatric solid tumors. Prognosis in advanced disease is poor. MicroRNAs (miRNAs) are short non-coding RNAs that control gene expression and can be used for prognostication, treatment resistance identification, and new therapeutics in soft tissue sarcomas.
Article
Oncology
Jae Hong Ryu, Juma Rahman, Shaneel Deo, Michael Flint
Summary: This study investigated the effects of time to treatment initiation (TTI) for soft tissue sarcomas (STS). The results showed that TTI over 30 days was not associated with higher distant metastasis, but was associated with better distant metastasis-free survival. Despite treatment delays caused by the COVID-19 pandemic, TTI over 30 days did not negatively impact patients.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Review
Cell Biology
Shadi Hames-Fathi, Steven W. G. Nottley, Nischalan Pillay
Summary: This article reviews recent advances in the diagnosis and treatment of undifferentiated soft tissue sarcoma (USTS), including genomic sequencing, cancer evolution and heterogeneity studies, and immunotherapy. The critical role of pathologists in the diagnosis and treatment of USTS patients is emphasized.
Review
Oncology
Mia C. Weiss
Summary: As the population ages, the incidence and prevalence of soft tissue sarcoma (STS) among geriatric patients will increase. Geriatric patients are more vulnerable to disease-related symptoms and have more difficulty tolerating treatment side effects. However, there is a lack of treatment guidelines for this specific patient population, making it crucial to consider individual fitness and co-morbidities when selecting treatment plans. Current research on advanced or metastatic STS in older adults highlights the underrepresentation of this patient population in clinical trials.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Oncology
Markus Albertsmeier, Annelore Altendorf-Hofmann, Lars H. Lindner, Rolf D. Issels, Eric Kampmann, Hans-Roland Duerr, Martin K. Angele, Frederick Klauschen, Jens Werner, Achim A. Jungbluth, Thomas Knoesel
Summary: This study demonstrates that VISTA is broadly expressed across subtypes of soft tissue sarcoma and is associated with increased tumor-infiltrating lymphocytes, PD-1, PD-L1, and CD3 expression. Patients with VISTA(+) tumors exhibit improved survival.
Article
Oncology
Miriam Rauch, Abbas Agaimy, Sabine Semrau, Alexander Willner, Oliver Ott, Rainer Fietkau, Werner Hohenberger, Roland S. Croner, Robert Grutzmann, Katja Fechner, Nikolaos Vassos
Summary: Multimodal treatment strategies in patients with soft tissue sarcoma of the extremities lead to excellent oncological outcomes. High-risk patients benefit from neoadjuvant treatment with lower risk of distant metastasis. However, neoadjuvant treatment is associated with a higher probability of postoperative but well-manageable complications.
Review
Medicine, General & Internal
Grace C. Blitzer, Poonam Yadav, Zachary S. Morris
Summary: Soft tissue sarcomas are rare tumors that primarily occur in the extremities, trunk, and retroperitoneum. Surgical resection with clear margins is the main treatment option for localized tumors, while radiation therapy can be used to reduce local recurrence. MRI-guided radiotherapy offers advantages in target delineation and differentiation from normal tissues, particularly for unresectable tumors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Alessandra Buja, Massimo Rugge, Matteo Barillaro, Andrea Miatton, Saveria Tropea, Claudia Cozzolino, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Antonella Brunello, Vincenzo Baldo, Carlo Riccardo Rossi, Simone Mocellin
Summary: This study aimed to compare the pathological and clinical features of retroperitoneal soft-tissue sarcomas (RPS) and non-RPS, and analyze if the hazard ratio for short-term mortality differs between RPS and non-RPS after adjusting for baseline differences. The analysis found that RPS accounted for 22.8% of cases, with different characteristics compared to non-RPS. The retroperitoneum site was an independent prognostic factor associated with worse overall survival in sarcoma patients.
Article
Oncology
B. Alvarez, A. Montero, R. Alonso, J. Valero, M. Lopez, R. Ciervide, E. Sanchez, O. Hernando, M. Garcia-Aranda, J. Marti, A. Prado, X. Chen-Zhao, C. Rubio
Summary: LDRT is a safe and effective treatment for HOA, providing pain relief and improving functionality. Further studies are needed to confirm these promising results.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)
Article
Oncology
Sylvie Bonvalot, Piotr L. Rutkowski, Juliette Thariat, Sebastien Carrere, Anne Ducassou, Marie-Pierre Sunyach, Peter Agoston, Angela M. Hong, Augustin Mervoyer, Marco Rastrelli, Victor Moreno, Rubi K. Li, Beatrice J. Tiangco, Antonio Casado Herra, Alessandro Gronchi, Teresa Sy-Ortin, Peter Hohenberger, Thierry de Baere, Axel Le Cesne, Sylvie Helfre, Esma Saada-Bouzid, Rodica M. Anghel, Guy Kantor, Angel Montero, Herbert H. Loong, Ramona Verges, Gabriel Kacso, Lyn Austen, Vincent F. Servois, Eva Wardelmann, Mikaela Dimitriu, Patricia Said, Alexander J. Lazar, Judith V. M. G. Bovee, Cecile Le Pechoux, Zsusanna Papai
Summary: The study Act.In.Sarc demonstrated that NBTXR3, a first-in-class radioenhancer, activated by preoperative radiation therapy, can improve the pathologic complete response rate and achieve R0 resections in patients with locally advanced soft tissue sarcoma. The study also showed that NBTXR3 does not negatively impact health-related quality of life and safety.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Biochemistry & Molecular Biology
Elisabet Rodriguez-Tomas, Johana C. Acosta, Laura Torres-Royo, Gabriel De Febrer, Gerard Baiges-Gaya, Helena Castane, Andrea Jimenez, Carlos Vasco, Pablo Araguas, Junior Gomez, Barbara Malave, Miguel Arquez, David Calderon, Berta Pique, Manel Algara, Angel Montero, Josep M. Simo, Xavier Gabaldo-Barrios, Sebastia Sabater, Jordi Camps, Jorge Joven, Meritxell Arenas
Summary: The aim of this study was to investigate the effects of low-dose radiotherapy (LDRT) on the levels of antioxidant enzyme paraoxonase-1 (PON1) and inflammatory markers in COVID-19 pneumonia patients. The results showed that LDRT had a beneficial impact on patients, improving respiratory function and radiological images. At one week after LDRT, serum PON1 activity increased and TGF-beta 1 concentrations decreased, suggesting a potential mediating effect.
Review
Oncology
Cynthia Aristei, Yasemin Bolukbasi, Orit Kaidar-Person, Raphael Pfeffer, Meritxell Arenas, Liesbeth J. Boersma, Antonella Ciabattoni, Charlotte E. Coles, Pierfrancesco Franco, Marco Krengli, Maria Cristina Leonardi, Fabio Marazzi, Valeria Masiello, Icro Meattini, Angel Montero, Birgitte Offersen, Maria Lurdes Trigo, Celine Bourgier, Domenico Genovesi, Vassilis Kouloulias, Alessio G. Morganti, Bruno Meduri, Nadia Pasinetti, Sara Pedretti, Elisabetta Perrucci, Sofia Rivera, Vincenzo Tombolini, Cristiana Vidali, Vincenzo Valentini, Philip Poortmans
Summary: This paper reports on the third Assisi Think Tank Meeting (ATTM) on breast cancer, which aimed to identify key clinical questions and areas requiring research to improve management and outcomes. The meeting discussed three main topics and proposed research protocols to address clinical challenges in these areas.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Raquel Ciervide, Angel Montero, Eduardo Garcia-Rico, Mariola Garcia-Aranda, Mercedes Herrero, Jessica Skaarup, Leticia Benassi, Maria Jose Barrera, Estela Vega, Beatriz Rojas, Raquel Bratos, Ana Luna, Manuela Parras, Maria Lopez, Ana Delgado, Paloma Quevedo, Silvia Castilla, Margarita Feyjoo, Ana Higueras, Mario Prieto, Ana Suarez-Gauthier, Lina Garcia-Canamaque, Nieves Escolan, Beatriz Alvarez, Xin Chen, Rosa Alonso, Mercedes Lopez, Ovidio Hernando, Jeannette Valero, Emilio Sanchez, Eva Ciruelos, Carmen Rubio
Summary: The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio-chemotherapy in breast cancer patients. The study found that primary concurrent radio-chemotherapy is feasible, with acceptable tolerance and high rates of pathological response.
Article
Oncology
M. Arenas, B. Pique, L. Torres-Royo, J. C. Acosta, E. Rodriguez-Tomas, G. De Febrer, C. Vasco, P. Araguas, J. A. Gomez, B. Malave, M. Arquez, M. Algara, A. Montero, M. Montero, J. M. Simo, X. Gabaldo, D. Parada, F. Riu, S. Sabater, J. Camps, J. Joven
Summary: Lung low-dose radiotherapy (LD-RT) is effective in treating patients with COVID-19 pneumonia, as it improves respiratory parameters, reduces hospitalization duration, and decreases the 1-month mortality rate compared to standard of care (SoC) alone.
STRAHLENTHERAPIE UND ONKOLOGIE
(2023)
Review
Oncology
Angel Montero, Beatriz Alvarez
Summary: Although benign diseases do not directly cause death, they still cause significant harm to patients' health due to pain, reduced functionality, increased disability, and negative impact on quality of life. Despite the demonstrated efficacy of radiotherapy in many non-tumorous diseases, there is still resistance to considering it as a valid and acceptable alternative.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY
(2023)
Article
Oncology
Angel Montero, Raquel Ciervide, Carmen Canadillas, Beatriz Alvarez, Mariola Garcia-Aranda, Rosa Alonso, Mercedes Lopez, Chen-Zhao Xin, Leyre Alonso, Jeannete Valero, Emilio Sanchez, Ovidio Hernando, Paz Garcia de Acilu, Pedro Fernandez-Leton, Carmen Rubio
Summary: This study aims to investigate the feasibility and tolerance of ultra-hypofractionated whole-breast irradiation (WBI) plus simultaneous integrated boost (SIB) in 5 fractions over one week after breast conserving surgery (BCS). 383 patients with early breast cancer participated in the study, and the results showed that this treatment regimen had good tolerance and a high survival rate without local, regional, or distant relapse.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Angel Montero, Xin Chen-Zhao, Raquel Ciervide, Beatriz Alvarez, Alejandro Prado, Mercedes Lopez, Emilio Sanchez, Ovidio Hernando, Miguel Angel de la Casa, Mariola Garcia-Aranda, Jeannette Valero, Rosa Alonso, Pedro Fernandez-Leton, Carmen Rubio
Summary: This study evaluated the impact of moderate hypofractionated radiotherapy on pathologic response and oncologic outcomes in patients with limb and trunk soft tissue sarcoma (STS). The results showed that moderate hypofractionated radiotherapy could effectively reduce tumor cellularity and increase tumor necrosis, leading to favorable pathologic response. In addition, it was associated with improved survival rates and distant metastasis-free survival rates.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Raquel Ciervide, Ovidio Hernando, Mercedes Lopez, Angel Montero, Daniel Zucca, Emilio Sanchez, Beatriz Alvarez, Mariola Garcia-Aranda, Xin Chen Zhao, Jeannette Valero, Rosa Alonso, Jaime Marti, Miguel Angel de la Casa, Leire Alonso, Juan Garcia, Paz Garcia de Acilu, Alejandro Prado, Pedro Fernandez Leton, Carmen Rubio
Summary: This study evaluated the clinical outcomes of patients with spine metastases treated with SBRT. The results showed that SBRT was effective in providing pain relief and achieving local control. The overall survival rate was also relatively high.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Review
Oncology
Angel Montero, Raquel Ciervide
Summary: Radiation therapy, along with surgery and systemic treatment, plays a key role in managing breast cancer. However, there has been a shift towards administering systemic treatment before surgery, aiming to maximize its effectiveness and improve outcomes for patients. This change in approach also applies to radiation therapy, with preoperative administration being considered in selected cases. Advances in radiobiological knowledge and technological improvements support the safe and effective combination of radiation therapy with other treatments in the primary preoperative setting.
Review
Oncology
Icro Meattini, Carlotta Becherini, Liesbeth Boersma, Orit Kaidar-Person, Gustavo Nader Marta, Angel Montero, Birgitte Vrou Offersen, Marianne C. Aznar, Claus Belka, Adrian Murray Brunt, Samantha Dicuonzo, Pierfrancesco Franco, Mechthild Krause, Mairead MacKenzie, Tanja Marinko, Livia Marrazzo, Ivica Ratosa, Astrid Scholten, Elzbieta Senkus, Hilary Stobart, Philip Poortmans, Charlotte E. Coles
Summary: High-quality randomised clinical trials have shown that moderately fractionated breast radiotherapy is as effective as daily fractions with reduced toxicity. However, implementation of hypofractionation has been slow. This paper aims to support equitable access to evidence-based breast radiotherapy and facilitate the translation of new evidence into routine practice. The consensus from the European Society for Radiotherapy and Oncology states that moderately hypofractionated radiotherapy can be offered to any patient for whole breast, chest wall, and nodal volumes.
Meeting Abstract
Oncology
J. C. Acosta Arteaga, L. Torres Royo, E. Rodriguez-Tomas, G. De Febrer, C. Vasco, J. A. Gomez, P. Araguas, B. Malave, M. Arquez, M. Algara, A. Montero, M. Montero, J. M. Simo, X. Gavalda, B. Pique, D. Parada, S. Sabater, J. Camps, J. Joven, M. Arenas
RADIOTHERAPY AND ONCOLOGY
(2022)
Meeting Abstract
Oncology
X. Chen-Zhao, A. Montero, J. de las Heras, B. Alvarez, I. Barrientos, A. Prado, R. Ciervide, M. Lopez, M. Garcia-Aranda, E. Ortiz, M. Gutierrez, E. Sanchez, O. Hernando, M. A. De la Casa, J. Valero, R. Alonso, P. Fernandez-Leton, C. Rubio
RADIOTHERAPY AND ONCOLOGY
(2022)
Meeting Abstract
Oncology
M. Lopez Gonzalez, R. Ciervide, O. Hernando, E. Sanchez, A. Montero, M. Garcia-Aranda, B. Alvarez, X. Chen-Zhao, R. Alonso, J. Valero, P. Fernandez-Leton, C. Rubio
RADIOTHERAPY AND ONCOLOGY
(2021)